|Jmol-3D images||Image 1
|oral: 163±64 min
intravenous: 74.1±19.6 min
|Molar mass||284.25 g mol−1|
|Melting point||220–228 °C (428–442 °F)|
|Solubility in water||soluble|
|Solubility||soluble in methanol
slightly soluble in ethanol
negligible in chloroform, benzene
|LD50||285 mg/kg (mouse, i.v.)
280 mg/kg (rat, i.v.)
12.5 mg/kg (rabbit, i.v.)
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
Psilocybin[nb 1] (// SIL-ə-SY-bin) is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. The most potent are members of the genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects similar (in some aspects) to those of LSD, mescaline, and DMT. In general, the effects include euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and spiritual experiences, and can include possible adverse reactions such as nausea and panic attacks.
Imagery found on prehistoric murals and rock paintings of modern-day Spain and Algeria suggest that human usage of psilocybin mushrooms dates back thousands of years. In Mesoamerica, the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the 16th century. In a 1957 Life magazine article, American banker and ethnomycologist R. Gordon Wasson described his experiences ingesting psilocybin-containing mushrooms during a traditional ceremony in Mexico, introducing the drug to popular culture. Shortly afterward, the Swiss chemist Albert Hofmann isolated the active principle psilocybin from the mushroom Psilocybe mexicana. Hofmann's employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic psychotherapy. Although increasingly restrictive drug laws of the late 1960s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an entheogen (spirituality-enhancing agent) grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms.
Some users of the drug consider it an entheogen and a tool to supplement practices for transcendence, including meditation and psychonautics. The intensity and duration of the effects of psilocybin are variable, depending on species or cultivar of mushrooms, dosage, individual physiology, and set and setting, as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. The mind-altering effects of psilocybin typically last from two to six hours, although to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Psilocybin has a low toxicity and a relatively low harm potential, and reports of lethal doses of the drug are rare. Several modern bioanalytical methods have been adapted to rapidly and accurately screen the levels of psilocybin in mushroom samples and body fluids. Since the 1990s, there has been a renewal of scientific research into the potential medical and psychological therapeutic benefits of psilocybin for treating conditions including obsessive-compulsive disorder, cluster headaches, and anxiety related to terminal cancer. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and it has been classified as a scheduled drug by many national drug laws.
- 1 History
- 2 Occurrence
- 3 Chemistry
- 4 Toxicity and harm potential
- 5 Physiology
- 6 Effects
- 7 Mystical experiences
- 8 Medical research
- 9 Social and legal aspects
- 10 See also
- 11 Notes
- 12 References
- 13 External links
There is evidence to suggest that psychoactive mushrooms have been used by humans in religious ceremonies for thousands of years. Murals dated 9000 to 7000 BCE found in the Sahara desert in southeast Algeria depict horned beings dressed as dancers, clothed in garb decorated with geometrical designs, and holding mushroom-like objects. Parallel lines extend from the mushroom shapes to the center of the dancers' heads. 6,000-year-old pictographs discovered near the Spanish town of Villar del Humo illustrate several mushrooms that have been tentatively identified as Psilocybe hispanica, a hallucinogenic species native to the area. Archaeological artifacts from Mexico, as well as the so-called Mayan "mushroom stones" of Guatemala have also been interpreted by some scholars as evidence for ritual and ceremonial usage of psychoactive mushrooms in the Mayan and Aztec cultures of Mesoamerica. In Nahuatl, the language of the Aztecs, the mushrooms were called teonanácatl, or "God's flesh". Following the arrival of Spanish explorers to the New World in the 16th century, chroniclers reported the use of mushrooms by the natives for ceremonial and religious purposes. According to the Dominican friar Diego Durán in The History of the Indies of New Spain (published c. 1581), mushrooms were eaten in festivities conducted on the occasion of the accession to the throne of Aztec emperor Moctezuma II in 1502. The Franciscan friar Bernardino de Sahagún wrote of witnessing mushroom usage in his Florentine Codex (published 1545–1590), and described how some merchants would celebrate upon returning from a successful business trip by consuming mushrooms to evoke revelatory visions. After the defeat of the Aztecs, the Spanish forbade traditional religious practices and rituals that they considered "pagan idolatry", including ceremonial mushroom use. For the next four centuries, the Indians of Mesoamerica hid their use of entheogens from the Spanish authorities.
Although several psychedelic mushrooms are found in Europe, there is little documented usage of these species in Old World history. The few existing historical accounts about psilocybin mushrooms typically lack sufficient information to allow species identification, and usually refer to the nature of their effects. For example, Flemish botanist Carolus Clusius (1526–1609) described the bolond gomba (crazy mushroom), used in rural Hungary to prepare love potions. English botanist John Parkinson included details about a "foolish mushroom" in his 1640 herbal Theatricum Botanicum. The first reliably documented report of intoxication with Psilocybe semilanceata—Europe's most common and widespread psychedelic mushroom—involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's Green Park.
American banker and amateur ethnomycologist R. Gordon Wasson and his wife Valentina studied the ritual use of psychoactive mushrooms by the native population in the Mazatec village Huautla de Jiménez. In 1957, Wasson described the psychedelic visions that he experienced during these rituals in "Seeking the Magic Mushroom", an article published in the popular American weekly Life magazine. Later the same year they were accompanied on a follow-up expedition by French mycologist Roger Heim, who identified several of the mushrooms as Psilocybe species. Heim cultivated the mushrooms in France, and sent samples for analysis to Albert Hofmann, a chemist employed by the Swiss multinational pharmaceutical company Sandoz (now Novartis). Hofmann, who had in 1938 created LSD, led a research group that isolated and identified the psychoactive compounds from Psilocybe mexicana. Hofmann was aided in the discovery process by his willingness to ingest mushroom extracts to help verify the presence of the active compounds. He and his colleagues later synthesized a number of compounds chemically related to the naturally occurring psilocybin, to see how structural changes would affect psychoactivity. The new molecules differed from psilocybin in the position of the phosphoryl or hydroxyl group at the top of the indole ring, and in the numbers of methyl groups (CH3) and other additional carbon chains.
Two diethyl analogs (containing two ethyl groups in place of the two methyl groups) of psilocybin and psilocin were synthesized by Hofmann: 4-phosphoryloxy-N,N-diethyltryptamine, called CEY-19, and 4-hydroxy-N,N-diethyltryptamine, called CZ-74. Because their physiological effects last only about three and a half hours (about half as long as psilocybin), they proved more manageable in European clinics using "psycholytic therapy"—a form of psychotherapy involving the controlled use of psychedelic drugs. Sandoz marketed and sold pure psilocybin under the name Indocybin to physicians and clinicians worldwide. There were no reports of serious complications when psilocybin was used in this way.
In the early 1960s, Harvard University became a testing ground for psilocybin, through the efforts of Timothy Leary and his associates Ralph Metzner and Richard Alpert (who later changed his name to Ram Dass). Leary obtained synthesized psilocybin from Hofmann through Sandoz pharmaceutical. Some studies, such as the Concord Prison Experiment, suggested promising results using psilocybin in clinical psychiatry. According to a 2008 review of safety guidelines in human hallucinogenic research, however, Leary and Alpert's well-publicized termination from Harvard and later advocacy of hallucinogen use "further undermined an objective scientific approach to studying these compounds". In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs suffered negative press and faced increasingly restrictive laws. In the United States, laws were passed in 1966 that prohibited the production, trade, or ingestion of hallucinogenic drugs; Sandoz stopped producing LSD and psilocybin the same year. Further backlash against LSD usage swept psilocybin along with it into the Schedule I category of illicit drugs in 1970. Subsequent restrictions on the use of these drugs in human research made funding for such projects difficult to obtain, and scientists who worked with psychedelic drugs faced being "professionally marginalized".
Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the "entheogen of choice". This was due in large part to a wide dissemination of information on the topic, which included works such as those by author Carlos Castaneda, and several books that taught the technique of growing psilocybin mushrooms. One of the most popular of this latter group was published in 1976 under the pseudonyms O.T. Oss and O.N. Oeric by Jeremy Bigwood, Dennis J. McKenna, K. Harrison McKenna, and Terence McKenna, entitled Psilocybin: Magic Mushroom Grower's Guide. Over 100,000 copies were sold by 1981. As ethnobiologist Jonathan Ott explains, "These authors adapted San Antonio's technique (for producing edible mushrooms by casing mycelial cultures on a rye grain substrate; San Antonio 1971) to the production of Psilocybe [Stropharia] cubensis. The new technique involved the use of ordinary kitchen implements, and for the first time the layperson was able to produce a potent entheogen in his own home, without access to sophisticated technology, equipment or chemical supplies."
Because of a lack of clarity about laws about psilocybin mushrooms, retailers in the late 1990s and early 2000s (decade) commercialized and marketed them in smartshops in the Netherlands and the UK, and online. Several websites[nb 2] emerged that have contributed to the accessibility of information on description, use, effects and exchange of experiences among users. Since 2001, six EU countries have tightened their legislation on psilocybin mushrooms in response to concerns about their prevalence and increasing usage. In the 1990s, hallucinogens and their effects on human consciousness were again the subject of scientific study, particularly in Europe. Advances in neuropharmacology and neuropsychology, and the availability of brain imaging techniques have provided impetus for using drugs like psilocybin to probe the "neural underpinnings of psychotic symptom formation including ego disorders and hallucinations". Recent studies in the United States have attracted attention from the popular press and thrust psilocybin back into the limelight.
Psilocybin is present in varying concentrations in over 200 species of Basidiomycota mushrooms. In a 2000 review on the worldwide distribution of hallucinogenic mushrooms, Gastón Guzmán and colleagues considered these to be distributed amongst the following genera: Psilocybe (116 species), Gymnopilus (14), Panaeolus (13), Copelandia (12), Hypholoma (6), Pluteus (6), Inocybe (6), Conocybe (4), Panaeolina (4), Gerronema (2) and Agrocybe, Galerina and Mycena (1 species each). Guzmán increased his estimate of the number of psilocybin-containing Psilocybe to 144 species in a 2005 review. The majority of these are found in Mexico (53 species), with the remainder distributed in the US and Canada (22), Europe (16), Asia (15), Africa (4), and Australia and associated islands (19). In general, psilocybin-containing species are dark-spored, gilled mushrooms that grow in meadows and woods of the subtropics and tropics, usually in soils rich in humus and plant debris. Psilocybin mushrooms occur on all continents, but the majority of species are found in subtropical humid forests. Psilocybe species commonly found in the tropics include P. cubensis and P. subcubensis. P. semilanceata—considered by Guzmán to be the world's most widely distributed psilocybin mushroom—is found in Europe, North America, Asia, South America, Australia and New Zealand, but is entirely absent from Mexico. Although the presence or absence of psilocybin is not of much use as a chemotaxonomical marker at the familial level or higher, it is used to classify taxa of lower taxonomic groups.
|Maximum reported psilocybin concentrations (% dry weight) in 12 Psilocybe species|
Both the caps and the stems contain the psychoactive compounds, although the caps contain consistently more. The spores of these mushrooms do not contain psilocybin or psilocin. The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain. Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms. In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 1.5% of the dry weight) and depends on species, strain, growth and drying conditions, and mushroom size. Cultivated mushrooms have less variability in psilocybin content than wild mushrooms. The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years, while mushrooms stored fresh for four weeks contain only traces of the original psilocybin. The psilocybin contents of dried herbarium specimens of Psilocybe semilanceata in one study were shown to decrease with the increasing age of the sample: collections dated 11, 33, or 118 years old contained 0.84%, 0.67%, and 0.014% (all dry weight), respectively. Mature mycelia contain some psilocybin, while young mycelia (recently germinated from spores) lack appreciable amounts. Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds baeocystin and norbaeocystin, chemicals thought to be biogenic precursors. Although most species of psilocybin-containing mushrooms bruise blue when handled or damaged due to the oxidization of phenolic compounds, this reaction is not a definitive method of identification or determining a mushroom's potency.
Psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine or 4-PO-DMT) is a prodrug that is converted into the pharmacologically active compound psilocin in the body by a dephosphorylation reaction. This chemical reaction takes place under strongly acidic conditions, or under physiological conditions in the body, through the action of enzymes called alkaline phosphatases.
Psilocybin is a tryptamine compound with a chemical structure containing an indole ring linked to an ethylamine substituent. It is chemically related to the amino acid tryptophan, and is structurally similar to the neurotransmitter serotonin. Psilocybin is a member of the general class of tryptophan-based compounds that originally functioned as antioxidants in earlier life forms before assuming more complex functions in multicellular organisms, including humans. Other related indole-containing psychedelic compounds include dimethyltryptamine, found in many plant species and in trace amounts in some mammals, and bufotenine, found in the skin of psychoactive toads. Biosynthetically, the biochemical transformation from tryptophan to psilocybin involves several enzyme reactions: decarboxylation, methylation at the N9 position, 4-hydroxylation, and O-phosphorylation. Isotopic labeling experiments suggest that tryptophan decarboxylation is the initial biosynthetic step and that O-phosphorylation is the final step. The precise sequence of the intermediate enzymatic steps is not known with certainty, and the biosynthetic pathway may differ between species.
Psilocybin is an alkaloid that is soluble in water, methanol and aqueous ethanol, but insoluble in organic solvents like chloroform and petroleum ether. Its pKa values are estimated to be 1.3 and 6.5 for the two successive phosphate OH groups and 10.4 for the dimethylamine nitrogen, so in general it exists as a zwitterionic structure. Exposure to light is detrimental to the stability of aqueous solutions of psilocybin, and will cause it to rapidly oxidize—an important consideration when using it as an analytical standard. Osamu Shirota and colleagues reported a method for the large-scale synthesis of psilocybin without chromatographic purification in 2003. Starting with 4-hydroxyindole, they generated psilocybin from psilocin in 85% yield, a marked improvement over yields reported from previous syntheses. Purified psilocybin is a white, needle-like crystalline powder with a melting point between 220–228 °C (428–442 °F), and a slightly ammonia-like taste.
Several relatively simple chemical tests—commercially available as reagent testing kits—can be used to assess the presence of psilocybin in extracts prepared from mushrooms. The drug reacts in the Marquis test to produce a yellow color, and a green color in the Mandelin test. Neither of these tests, however, is specific for psilocybin; for example, the Marquis test will react with many classes of controlled drugs, such as those containing primary amino groups and unsubstituted benzene rings, including amphetamine and methamphetamine. Ehrlich's reagent and DMACA reagent are used as chemical sprays to detect the drug after thin layer chromatography. Many modern techniques of analytical chemistry have been used to quantify psilocybin levels in mushroom samples. Although the earliest methods commonly used gas chromatography, the high temperature required to vaporize the psilocybin sample prior to analysis causes it to spontaneously lose its phosphoryl group and become psilocin—making it difficult to chemically discriminate between the two drugs. In forensic toxicology, techniques involving gas chromatography coupled to mass spectrometry (GC–MS) are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures. These techniques include ion mobility spectrometry, capillary zone electrophoresis, ultraviolet spectroscopy, and infrared spectroscopy. High performance liquid chromatography (HPLC) is used with ultraviolet, fluorescence, electrochemical, and electrospray mass spectrometric detection methods.
Various chromatographic methods have been developed to detect psilocin in body fluids: the rapid emergency drug identification system (REMEDi HS), a drug screening method based on HPLC; HPLC with electrochemical detection; GC–MS; and liquid chromatography coupled to mass spectrometry. Although the determination of psilocin levels in urine can be performed without sample clean-up (i.e., removing potential contaminants that make it difficult to accurately assess concentration), the analysis in plasma or serum requires a preliminary extraction, followed by derivatization of the extracts in the case of GC–MS. A specific immunoassay has also been developed to detect psilocin in whole blood samples. A 2009 publication reported using HPLC to quickly separate forensically important illicit drugs including psilocybin and psilocin, which were identifiable within about half a minute of analysis time. These analytical techniques to determine psilocybin concentrations in body fluids are, however, not routinely available, and not typically used in clinical settings.
Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a partial agonist for several serotonergic receptors. Psilocin has a high affinity for the 5-HT2A serotonin receptor in the brain, where it mimics the effects of serotonin (5-hydroxytryptamine, or 5-HT). Psilocin binds less tightly to other serotonergic receptors 5-HT1A, 5-HT1D, and 5-HT2C. Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood and motivation. The psychotomimetic (psychosis-mimicking) effects of psilocin can be blocked in a dose-dependent fashion by the 5-HT2A antagonist drugs ketanserin and risperidone. Although the 5-HT2A receptor is responsible for most of the effects of psilocin, various lines of evidence have shown that interactions with non-5-HT2A receptors also contribute to the subjective and behavioral effects of the drug.[nb 3] For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia, and some psychotomimetic symptoms of psilocin are reduced by haloperidol, a non-selective dopamine receptor antagonist. Taken together, these suggest that there may be an indirect dopaminergic contribution to psilocin's psychotomimetic effects. In contrast to LSD, which binds to dopamine receptor D2, psilocybin and psilocin have no affinity for the dopamine D2 receptors.
The chemical structures of psilocybin and related analogs have been used in computational biology to help model the structure, function, and ligand-binding properties of the 5-HT2C G-protein-coupled receptor.
Toxicity and harm potential
The toxicity of psilocybin is low. In rats, the median lethal dose (LD50) when administered orally is 280 milligrams per kilogram (mg/kg), approximately one and a half times that of caffeine. When administered intravenously in rabbits, psilocybin's LD50 is approximately 12.5 mg/kg. Psilocybin comprises approximately 1% of the weight of Psilocybe cubensis mushrooms, and so nearly 1.7 kilograms (3.7 lb) of dried mushrooms, or 17 kilograms (37 lb) of fresh mushrooms, would be required for a 60-kilogram (130 lb) person to reach the 280 mg/kg LD50 value of rats. Based on the results of animal studies, the lethal dose of psilocybin has been extrapolated to be 6 grams, 1000 times greater than the effective dose of 6 milligrams. The Registry of Toxic Effects of Chemical Substances assigns psilocybin a relatively high therapeutic index of 641 (higher values correspond to a better safety profile); for comparison, the therapeutic indices of aspirin and nicotine are 199 and 21, respectively. The lethal dose from psilocybin toxicity alone is unknown at recreational or medicinal levels, and has rarely been documented—as of 2011, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature, and even of these documented cases may involve other factors aside from just psilocybin.[nb 4]
Most of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. Probably the most common cause of hospital admissions resulting from magic mushroom usage involve "bad trips" or panic reactions, in which affected individuals become extremely anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes.
Repeated use of psilocybin does not lead to physical dependence. A 2008 study concluded that, based on US data from the period 2000–2002, adolescent-onset (defined here as ages 11–17) usage of hallucinogenic drugs (including psilocybin) did not increase the risk of drug dependence in adulthood; this was in contrast to adolescent usage of cannabis, cocaine, inhalants, anxiolytic medicines, and stimulants, all of which were associated with "an excess risk of developing clinical features associated with drug dependence". Likewise, a 2010 Dutch study ranked the relative harm of psilocybin mushrooms compared to a selection of 19 recreational drugs, including alcohol, cannabis, cocaine, ecstasy, heroin, and tobacco. Magic mushrooms were ranked as the illicit drug with the lowest harm, corroborating conclusions reached earlier by expert groups in the United Kingdom.
Although psilocybin may be prepared synthetically, outside of the research setting, it is not typically used in this form. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing a herbal tea, or by combining with other foods to mask the bitter taste. In rare cases people have injected mushroom extracts intravenously. The effects of the drug begin 10–40 minutes after ingestion, and last 2–6 hours depending on dose, species, and individual metabolism. The half life of psilocybin is 163 ± 64 minutes when taken orally, or 74.1 ± 19.6 minutes when injected intravenously. A dosage of 4–10 mg, corresponding roughly to 50–300 micrograms per kilogram (µg/kg) of body weight, is required to induce psychedelic effects. A typical recreational dosage is 10–50 mg psilocybin, which is roughly equivalent to 10–50 grams of fresh mushrooms, or 1–5 grams of dried mushrooms. A small number of people are unusually sensitive to psilocybin, such that a normally threshold-level dose of about 2 mg can result in effects usually associated with medium or high doses. In contrast, there are some who require relatively high doses to experience noticeable effects. Individual brain chemistry and metabolism play a large role in determining a person's response to psilocybin.
Psilocybin is metabolized mostly in the liver. As it becomes converted to psilocin, it undergoes a first-pass effect, whereby its concentration is greatly reduced before it reaches the systemic circulation. Psilocin is broken down by the enzyme monoamine oxidase to produce several metabolites that can circulate in the blood plasma, including 4-hydroxyindole-3-acetaldehyde, 4-hydroxytryptophol, and 4-hydroxyindole-3-acetic acid. Some psilocin is not broken down by enzymes and instead forms a glucuronide; this is a biochemical mechanism animals use to eliminate toxic substances by linking them with glucuronic acid, which can then be excreted in the urine. Psilocin is glucuronated by the glucuronosyltransferase enzymes UGT1A9 in the liver, and by UGT1A10 in the small intestine. Based on studies using animals, about 50% of ingested psilocybin is absorbed through the stomach and intestine. Within 24 hours, about 65% of the absorbed psilocybin is excreted into the urine, and a further 15–20% is excreted in the bile and feces. Although most of the remaining drug is eliminated in this way within 8 hours, it is still detectable in the urine after 7 days. Clinical studies show that psilocin concentrations in the plasma of adults average about 8 µg/liter within 2 hours after ingestion of a single 15 mg oral psilocybin dose; psychological effects occur with a blood plasma concentration of 4–6 µg/liter. Psilocybin is about 100 times less potent than LSD on a weight per weight basis, and the physiological effects last about half as long.
Tolerance to psilocybin builds and dissipates quickly; ingesting psilocybin more than about once a week can lead to diminished effects. Tolerance dissipates after a few days, so doses can be spaced several days apart to avoid the effect. A cross-tolerance can develop between psilocybin and the pharmacologically similar LSD, and between psilocybin and phenethylamines such as mescaline and DOM. Monoamine oxidase inhibitors (MAOI) have been known to prolong and enhance the effects of psilocybin. Alcohol consumption may enhance the effects of psilocybin, because acetaldehyde, one of the primary breakdown metabolites of consumed alcohol, reacts with biogenic amines present in the body to produce MAOIs related to tetrahydroisoquinoline and β-carboline. Tobacco smokers can also experience more powerful effects with psilocybin, because tobacco smoke exposure decreases levels of MAO in the brain and peripheral organs.
The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly referred to as set and setting. In the early 1960s, Timothy Leary and colleagues at Harvard University investigated the role of set and setting on the effects of psilocybin. They administered the drug to 175 volunteers from various backgrounds in an environment intended to be similar to a comfortable living room. Ninety-eight of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Individuals who had experience with psilocybin prior to the study reported more pleasant experiences than those for whom the drug was novel. Group size, dosage, preparation, and expectancy were important determinants of the drug response. In general, those placed in groups of more than eight individuals felt that the groups were less supportive, and their experiences were less pleasant. Conversely, smaller groups (fewer than six individuals) were seen as more supportive. Participants also reported having more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making an individual more receptive to interpersonal interactions and environmental stimuli. These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dosage, set, and setting were fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.
After ingesting psilocybin, a wide range of subjective effects may be experienced: feelings of disorientation, lethargy, giddiness, euphoria, joy, and depression. About a third of users report feelings of anxiety or paranoia. Low doses of the drug can induce hallucinatory effects. Closed-eye hallucinations may occur, in which the affected individual sees multicolored geometric shapes and vivid imaginative sequences. Some individuals report experiencing synesthesia, such as tactile sensations when viewing colors. At higher doses, psilocybin can lead to "Intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones". Open-eye visual hallucinations are common, and may be very detailed although rarely confused with reality.
A 2011 prospective study by Roland R. Griffiths and colleagues suggests that a single high dosage of psilocybin can cause long-term changes in the personality of its users. About half of the study participants—described as healthy, "spiritually active", and many possessing postgraduate degrees—showed an increase in the personality dimension of openness (assessed using the Revised NEO Personality Inventory), and this positive effect was apparent more than a year after the psilocybin session. According to the study authors, the finding is significant because "no study has prospectively demonstrated personality change in healthy adults after an experimentally manipulated discrete event." Although other researchers have described instances of psychedelic drug usage leading to new psychological understandings and personal insights, it is not known whether these experimental results can be generalized to larger populations.
Common responses include: pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions).[nb 5] The temporary increases in blood pressure caused by the drug can be a risk factor for users with pre-existing hypertension. These qualitative somatic effects caused by psilocybin have been corroborated by several early clinical studies. A 2005 magazine survey of club goers in the UK found that nausea or vomiting was experienced by over a quarter of those who had used hallucinogenic mushrooms in the last year, although this effect is caused by the mushroom rather than psilocybin itself. In one study, administration of gradually increasing dosages of psilocybin daily for 21 days had no measurable effect on electrolyte levels, blood sugar levels, or liver toxicity tests.
Psilocybin is known to strongly influence the subjective experience of the passage of time. Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still". Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred tapping rate. These results are consistent with the drug's role in affecting prefrontal cortex activity, and the role that the prefrontal cortex is known to play in time perception. However, the neurochemical basis of psilocybin's effects on the perception of time are not known with certainty.
Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "bad trip") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. In general, the phrase "bad trip" is used to describe a reaction that is characterized primarily by fear or other unpleasant emotions, not just transitory experience of such feelings. A variety of factors may contribute to a psilocybin user experiencing a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: set and setting). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip. Other than the duration of the experience, the effects of psilocybin are similar to comparable dosages of LSD or mescaline. However, in the Psychedelics Encyclopedia, author Peter Stafford noted, "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."
Possible adverse psychiatric effects
Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violence, aggression, homicidal and suicidal attempts, prolonged schizophrenia-like psychosis, and convulsions have been reported in the literature. A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a panic attack. Other adverse effects less frequently reported include paranoia, confusion, derealization, disconnection from reality, and mania. Psilocybin usage can temporarily induce a state of depersonalization disorder. Usage by those with schizophrenia can induce acute psychotic states requiring hospitalization.
The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and neuroimaging studies of this psychotic disorder. In both cases, psychotic symptoms are thought to arise from a "deficient gating of sensory and cognitive information" in the brain that ultimately lead to "cognitive fragmentation and psychosis". Flashbacks (spontaneous recurrences of a previous psilocybin experience) can occur long after having used psilocybin mushrooms. Hallucinogen persisting perception disorder (HPPD) is characterized by a continual presence of visual disturbances similar to those generated by psychedelic substances. Neither flashbacks nor HPPD are commonly associated with psilocybin usage, and correlations between HPPD and psychedelics are further obscured by polydrug use and other variables.
Psilocybin mushrooms have been and continue to be used in indigenous New World cultures in religious, divinatory, or spiritual contexts. Reflecting the meaning of the word entheogen ("the god within"), the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds. Typically used in small group community settings, they enhance group cohesion and reaffirm traditional values. Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced self-awareness and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature.
Psychedelic drugs can induce states of consciousness that have lasting personal meaning and spiritual significance in individuals who are religious or spiritually inclined; these states are called mystical experiences. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through non-drug techniques, such as meditation or holotropic breathwork. In the 1960s, Walter Pahnke and colleagues systematically evaluated mystical experiences (which they called "mystical consciousness") by categorizing their common features. These categories, according to Pahnke, "describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations", and allow researchers to assess mystical experiences on a qualitative, numerical scale.
In the 1962 Marsh Chapel Experiment, which was run by Pahnke at the Harvard Divinity School under the supervision of Timothy Leary, almost all of the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences. One of the participants was religious scholar Huston Smith, author of several textbooks on comparative religion; he later described his experience as "the most powerful cosmic homecoming I have ever experienced." In a 25-year followup to the experiment, all of the subjects given psilocybin described their experience as having elements of "a genuine mystical nature and characterized it as one of the high points of their spiritual life". Psychedelic researcher Rick Doblin considered the study partially flawed due to incorrect implementation of the double-blind procedure, and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast "a considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects". This sentiment was echoed by psychiatrist William A. Richards, who in a 2007 review stated "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry."
A group of researchers from Johns Hopkins School of Medicine led by Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure. When asked in an interview about the similarity of his work with Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s." The National Institute of Drug Abuse-funded study, published in 2006, has been praised by experts for the soundness of its experimental design.[nb 6] In the experiment, 36 volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood; 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme "experience of fear" or dysphoria (i.e., a "bad trip") at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session); about one-third of these (13% of the total) reported that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject's sense of well-being.
A follow-up study conducted 14 months after the original psilocybin session confirmed that participants continued to attribute deep personal meaning to the experience. Almost one-third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it among their five most spiritually significant events. About two-thirds indicated that the experience increased their sense of well-being or life satisfaction. Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness/Intellect; personality traits are normally stable across the lifespan for adults. Likewise, in a recent (2010) web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.
In 2011, Griffiths and colleagues published the results of further studies designed to learn more about the optimum psilocybin doses needed for positive life-changing experiences, while minimizing the chance of negative reactions. In a 14-month followup, the researchers found that 94% of the volunteers rated their experiences with the drug as one of the top five most spiritually significant of their lives (44% said it was the single most significant). None of the 90 sessions that took place throughout the study were rated as decreasing well-being or life satisfaction. Moreover, 89% reported positive changes in their behaviors as a result of the experiences. The conditions of the experimental design included a single drug experience a month, on a couch, in a living-room-like setting, with eye shades and carefully chosen music (classical and world music). As an additional precaution to guide the experience, as with the 2006 study, the 2011 study included a "monitor" or "guide" whom the volunteers supposedly trusted. The monitors provided gentle reassurance when the volunteers experienced anxiety. The volunteers and monitors all remained blind to the exact dosages for the sake of the experiment.
Psilocybin has been a subject of medical research since the 1960s, when Leary and Alpert ran the Harvard Psilocybin Project, in which they carried out a number of experiments to evaluate the therapeutic value of psilocybin in the treatment of personality disorders, or to augment psychological counseling. In the 2000s (decade), there was a renewal of research concerning the use of psychedelic drugs for potential clinical applications, such as to address anxiety disorders, major depression, and various addictions. In 2008, the Johns Hopkins research team published guidelines for responsibly conducting medical research trials with psilocybin and other hallucinogens in humans. These included recommendations on how to screen potential study volunteers to exclude those with personal or family psychiatric histories that suggest a risk of adverse reactions to hallucinogens. A 2010 study on the short- and long-term subjective effects of psilocybin administration in clinical settings concluded that despite a small risk of acute reactions such as dysphoria, anxiety, or panic, "the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk"; the authors note, however, that the safety of the drug "cannot be generalized to situations in which psilocybin is used recreationally or administered under less controlled conditions."
The first clinical study of psilocybin approved by the U.S. Food and Drug Administration (FDA) since 1970—led by Francisco Moreno at the University of Arizona and supported by the Multidisciplinary Association for Psychedelic Studies—studied the effects of psilocybin on patients with obsessive–compulsive disorder (OCD). The pilot study found that, when administered by trained professionals in a medical setting, the use of psilocybin was associated with substantial reductions in OCD symptoms in several of the patients. This effect is caused largely by psilocybin's ability to reduce the levels of the 5-HT2A receptor, resulting in decreased responsiveness to serotonin. Psilocybin has additionally shown promise to ease the pain caused by cluster headaches, "one of the worst pain syndromes known to mankind." In a 2006 study, half of cluster headache patients reported that psilocybin aborted the attacks, and most reported extended remission periods; similar results were reported for LSD. A 2011 review of alternative headache treatments concluded that, despite flaws in the study design, these results suggest that LSD and psilocybin may warrant further study for use in the prevention of cluster headaches—only subhallucinogenic doses of the drugs are required for effective treatment, and no other medications have been reported to stop a cluster headache cycle.
Several modern studies have investigated the possibility that psilocybin can ease the psychological suffering associated with end-stage cancer. Preliminary results indicate that low doses of psilocybin can improve the mood and reduce the anxiety of patients with advanced cancer, and that the effects last from two weeks to six months. These results are comparable to those obtained from early studies that explored the use of LSD to improve the psychological well-being of terminally ill patients, but without the experimental rigor employed in modern clinical psychopharmacology research.
Social and legal aspects
A 2009 national survey of drug use by the US Department of Health and Human Services concluded that the number of first-time psilocybin mushroom users in the United States was roughly equivalent to the number of first-time users of marijuana. In European countries, the lifetime prevalence estimates of psychedelic mushroom usage among young adults (15–34 years) range from 0.3% to 14.1%. In modern Mexico, traditional ceremonial use survives among several indigenous groups, including the Nahuatls, the Matlatzinca, the Totonacs, the Mazatecs, Mixes, Zapotecs, and the Chatino. Although hallucinogenic Psilocybe species are abundant in low-lying areas of Mexico, most ceremonial use takes places in mountainous areas of elevations greater than 1,500 meters (4,900 ft). Guzmán suggests this is a vestige of Spanish colonial influence from several hundred years earlier, when mushroom use was persecuted by the Catholic Church.
In the United States, psilocybin (and psilocin) were first subjected to federal regulation by the Drug Abuse Control Amendments of 1965, a product of a bill sponsored by Senator Thomas J. Dodd. The law—passed in July 1965 and effected on February 1, 1966—was an amendment to the federal Food, Drug and Cosmetic Act and was intended to regulate the unlicensed "possession, manufacture, or sale of depressant, stimulant and hallucinogenic drugs". The statutes themselves, however, did not list the "hallucinogenic drugs" that were being regulated. Instead, the term "hallucinogenic drugs" was meant to refer to those substances believed to have a "hallucinogenic effect on the central nervous system".
Despite the seemingly strict provisions of the law, many people were exempt from prosecution. The statutes "permit[ted] … people to possess such drugs so long as they were for the personal use of the possessor, [for] a member of his household, or for administration to an animal". The federal law that specifically banned psilocybin and psilocin was enacted on October 24, 1968. The substances were said to have "a high potential for abuse", "no currently accepted medical use," and "a lack of accepted safety". On October 27, 1970, both psilocybin and psilocin became classified as Schedule I drugs and were simultaneously labeled "hallucinogens" under a section of the Comprehensive Drug Abuse Prevention and Control Act known as the Controlled Substances Act. Schedule I drugs are illicit drugs that are claimed to have no known therapeutic benefit. The United Nations Convention on Psychotropic Substances (adopted in 1971) requires its members to prohibit psilocybin, and parties to the treaty are required to restrict use of the drug to medical and scientific research under strictly controlled conditions. However, the mushrooms containing the drug were not specifically included in the convention, due largely to pressure from the Mexican government. Most national drug laws have been amended to reflect the terms of the convention; examples include the UK Misuse of Drugs Act 1971, the US Psychotropic Substances Act of 1978, the Canadian Controlled Drugs and Substances Act of 1996, and the Japanese Narcotics and Psychotropics Control Law of 2002. The possession and use of psilocybin is prohibited under almost all circumstances, and often carries severe legal penalties.
Possession and use of psilocybin mushrooms, including the bluing species of Psilocybe, is therefore prohibited by extension. However, in many national, state, and provincial drug laws, there has been a great deal of ambiguity about the legal status of psilocybin mushrooms, as well as a strong element of selective enforcement in some places. Most US state courts have considered the mushroom a 'container' of the illicit drugs, and therefore illegal. A loophole further complicates the legal situation—the spores of psilocybin mushrooms do not contain the drugs, and are legal to possess in many areas. Jurisdictions that have specifically enacted or amended laws to criminalize the possession of psilocybin mushroom spores include Germany (since 1998), and California, Georgia, and Idaho in the United States. As a consequence, there is an active underground economy involved in the sale of spores and cultivation materials, and an internet-based social network to support the illicit activity. After a long interruption in the use of psilocybin in research, there has been a general shift in attitudes regarding research with hallucinogenic agents. Many countries are revising their positions and have started to approve studies to test the physiological and therapeutic effects of hallucinogens.
- Synonyms and alternate spellings include: psilocybine, psilocibin, psilocybinum, psilotsibin, psilocin phosphate ester, teonanacatl, and Indocybin.
- The EMCDDA lists the general-purpose websites Erowid, Lycaeum, Mycotopia, The Shroomery, MushroomJohn and The Entheogen Review. Regional sites focusing on hallucinogenic mushrooms listed were Copenhagen Mushroom Link (Denmark), Champis (France), Daath (Hungary), Delysid (Spain), Enteogeneos (Portugal), Kouzelné houbičky (Czech Republic), Norshroom (Norway), Planetahongo (Spain), Svampinfo (Sweden), and Taikasieniforum (Finland). It also listed Magic-Mushrooms.net. The report detailed several additional sites selling spore prints in 2006, but noted that many of these had ceased operation.
- Subjective effects are "feelings, perceptions, and moods personally experienced by an individual"; they are often assessed using methods of self-report, including questionnaires. Behavioral effects, in contrast, can be observed directly.
- One of the reported fatalities, that of a 22-year old French man who died in 1993, was later challenged in the literature by Jochen Gartz and colleagues, who concluded "the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality".
- Percentages are derived from a non-blind clinical study of 30 individuals who were given a dosage of 8–12 milligrams of psilocybin; from Passie (2002), citing Quentin (1960).
- The academic communities' approval for the methodology employed is exemplified by the quartet of commentaries published in the journal Psychopharmacology titled "Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths et al.", by HD Kleber (pp. 291–2), DE Nichols (pp. 284–6), CR Schuster (pp. 289–90), and SH Snyder (pp. 287–8).
- Passie T, Seifert J, Schneider U, Emrich HM. (2002). "The pharmacology of psilocybin". Addiction Biology 7 (4): 357–64. doi:10.1080/1355621021000005937. PMID 14578010.
- Merck Index, 11th Edition, 7942
- "Psilocybine – Compound Summary". PubChem. National Library of Medicine. Retrieved 2011-12-04.
- Samorini G. (1992). "The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000–7000 B.P.)". Integration 2 (3): 69–78.
- Akers BP, Ruiz JF, Piper A, Ruck CA. (2011). "A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms?". Economic Botany 65 (2): 121–8. doi:10.1007/s12231-011-9152-5.
- Stamets (1996), p. 11.
- Marley (2010), p. 164.
- Hofmann A. (1980). "The Mexican relatives of LSD". LSD: My Problem Child. New York, New York: McGraw-Hill. pp. 49–71. ISBN 978-0-07-029325-0.
- Marley (2010), p. 165.
- Gartz (1997), pp. 10–2.
- Gartz (1997), p. 16.
- Wasson RG. (13 May 1957). "Seeking the magic mushroom". Life (Time Inc.): 101–20. ISSN 0024-3019.
- Heim R. (1957). "Notes préliminaires sur les agarics hallucinogènes du Mexique" [Preliminary notes on the hallucination-producing agarics of Mexico]. Revue de Mycologie (in French) 22 (1): 58–79.
- Hofmann A, Heim R, Brack A, Kobel H. (1958). "Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim" [Psilocybin, a psychotropic drug from the Mexican magic mushroom Psilocybe mexicana Heim]. Experientia (in German) 14 (3): 107–9. doi:10.1007/BF02159243. PMID 13537892.
- Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H, Petrzilka T, Troxler F. (1959). "Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen" [Psilocybin and psilocin, two psychotropic substances in Mexican magic mushrooms]. Helvetica Chimica Acta (in German) 42 (5): 1557–72. doi:10.1002/hlca.19590420518.
- Stafford (1992), p. 237.
- Marley (2010), p. 166.
- Leary T, Litwin GH, Metzner R. (1963). "Reactions to psilocybin administered in a supportive environment". Journal of Nervous and Mental Disease 137 (6): 561–73. doi:10.1097/00005053-196312000-00007. PMID 14087676.
- Leary T, Metzner R, Presnell M, Weil G, Schwitzgebel R, Kinne S. (1965). "A new behavior change program using psilocybin". Psychotherapy: Theory, Research & Practice 2 (2): 61–72. doi:10.1037/h0088612.
- Johnson MW, Richards WA, Griffiths RR. (2008). "Human hallucinogen research: guidelines for safety" (PDF). Journal of Psychopharmacology 22 (6): 603–20. doi:10.1177/0269881108093587. PMC 3056407. PMID 18593734.
- Matsushima Y, Eguchi F, Kikukawa T, Matsuda T. (2009). "Historical overview of psychoactive mushrooms" (PDF). Inflammation and Regeneration 29 (1): 47–58. doi:10.2492/inflammregen.29.47.
- Griffiths RR, Grob CS. (2010). "Hallucinogens as medicine" (PDF). Scientific American 303 (6): 77–9. doi:10.1038/scientificamerican1210-76.
- Ott (1993), p. 276.
- Oeric OT, Os ON. (1991). Psilocybin: Magic Mushroom Grower's Guide (2nd ed.). San Francisco, California: Quick American Archives. ISBN 978-0-932551-06-1.
- Ott (1993), p. 290. San Antonio's technique describes a method to grow the common edible mushroom Agaricus bisporus; see San Antonio JP. (1971). "A laboratory method to obtain fruit from cased grain spawn of the cultivated mushroom, Agaricus bisporus". Mycologia 63 (1): 16–21. doi:10.2307/3757680. JSTOR 3757680. PMID 5102274.
- Hillebrand J, Olszewski D, Sedefov R. (2006) (PDF). Hallucinogenic Mushrooms: An Emerging Trend Case Study (Report). Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). ISBN 92-9168-249-7. http://www.emcdda.europa.eu/attachements.cfm/att_31215_EN_TP_Hallucinogenic_mushroom.pdf.
- Studerus E, Kometer M, Hasler F, Vollenweider FX. (2011). "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies". Journal of Psychopharmacology 25 (11): 1434–52. doi:10.1177/0269881110382466. PMID 20855349.
- Keim B. (1 July 2008). "Psilocybin study hints at rebirth of hallucinogen research". Wired.com. Retrieved 2011-08-08.
- Miller G. (1 July 2008). "A very memorable trip". ScienceNow. Retrieved 2011-08-08.
- Guzmán G, Allen JW, Gartz J. (2000). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto: Sezione Archeologia, Storia, Scienze Naturali 14: 189–280.
- Guzmán G. (2005). "Species diversity of the genus Psilocybe (Basidiomycotina, Agaricales, Strophariaceae) in the world mycobiota, with special attention to hallucinogenic properties". International Journal of Medicinal Mushrooms 7 (1–2): 305–31. doi:10.1615/IntJMedMushr.v7.i12.
- Wurst et al. (2002), p. 5.
- Guzmán G. (1983). The Genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution, and Chemistry of the Hallucinogenic Species. Beihefte Zur Nova Hedwigia. Heft 74. Vaduz, Liechtenstein: J. Cramer. pp. 361–2. ISBN 978-3-7682-5474-8.
- Saupe SG. (1981). "Occurrence of psilocybin/psilocin in Pluteus salicinus (Plutaceae)". Mycologia 73 (4): 871–4. doi:10.2307/3759505. JSTOR 3759505.
- Stamets (1996), p. 39.
- Wurst M, Semerdžieva M, Vokoun J. (1984). "Analysis of psychotropic compounds in fungi of the genus Psilocybe by reversed-phase high performance liquid chromatography". Journal of Chromatography A 286: 229–35. doi:10.1016/S0021-9673(01)99190-3.
- Kysilka R, Wurst M. (1989). "High-performance liquid chromatographic determination of some psychotropic indole derivatives". Journal of Chromatography 464 (2): 434–7. PMID 2722990.
- Keller T, Schneider A, Regenscheit P, Dirnhofer R, Rücker T, Jaspers J, Kisser W. (1999). "Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry". Forensic Science International 99 (2): 93–105. doi:10.1016/S0379-0738(98)00168-6. PMID 10077856.
- Bigwood J, Beug MW. (1982). "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer". Journal of Ethnopharmacology 5 (3): 287–91. doi:10.1016/0378-8741(82)90014-9. PMID 7201054.
- Gartz J. (1992). "New aspects of the occurrence, chemistry and cultivation of European hallucinogenic mushrooms". Supplemento agli Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali 8: 107–24.
- Stafford (1992), p. 248.
- Stamets (1996), pp. 36–41, 52.
- "Drug profiles: Hallucinogenic mushrooms". European Monitoring Centre for Drugs and Drug Addiction. 19 September 2011. Retrieved 2011-12-04.
- Stamets (1996), pp. 51–2.
- van Amsterdam J, Opperhuizen A, van den Brink W. (2011). "Harm potential of magic mushroom use: a review". Regulatory Toxicology and Pharmacology 59 (3): 423–9. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914.
- Ohenoja E, Jokiranta J, Mäkinen T, Kaikkonen A, Airaksinen MM. (1987). "The occurrence of psilocybin and psilocin in Finnish fungi". Journal of Natural Products 50 (4): 741–4. doi:10.1021/np50052a030. PMID 3430170.
- Gross ST. (2000). "Detecting psychoactive drugs in the developmental stages of mushrooms". Journal of Forensic Sciences 45 (3): 527–37. PMID 10855955.
- Stamets (1996), p. 38.
- Ballesteros et al. (2006), p. 170.
- Stamets (1996), pp. 56–8.
- Azmitia EC. (2010). "Evolution of serotonin: sunlight to suicide". In Müller CP, Jacobs BL. Handbook of the Behavioral Neurobiology of Serotonin. London, UK: Academic Press. p. 7. ISBN 978-0-12-374634-4.
- Wurst et al. (2002), pp. 10–13.
- Agurell S, Nilsson JL. (1968). "Biosynthesis of psilocybin. Part II. Incorporation of labelled tryptamine derivatives". Acta Chemica Scandinavica 22 (4): 1210–8. doi:10.3891/acta.chem.scand.22-1210. PMID 5750023.
- Chilton WS, Bigwood J, Jensen RE. (1979). "Psilocin, bufotenine and serotonin: historical and biosynthetic observations". Journal of Psychedelic Drugs 11 (1–2): 61–9. doi:10.1080/02791072.1979.10472093. PMID 392119.
- Wurst et al. (2002), pp. 12–3.
- Wurst et al. (2002), p. 15.
- "Psilocybine". Hazardous Substances Data Bank. U.S. National Library of Medicine. Retrieved 2011-11-21.
- Anastos N, Barnett NW, Pfeffer FM. (2006). "Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography". Science & Justice 46 (2): 91–6. doi:10.1016/S1355-0306(06)71579-9.
- Shirota O, Hakamata W, Goda Y. (2003). "Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom"". Journal of Natural Products 66 (6): 885–7. doi:10.1021/np030059u. PMID 12828485.
- Troxler F, Seeman F, Hofmann A. (1959). "Abwandlungsprodukte von Psilocybin und Psilocin. 2. Mitteilung über synthetische Indolverbindungen" [Modified products of psilocybin and psilocin. 2. Report on synthetic indole compounds]. Helvetica Chimica Acta (in German) 42 (6): 2073–103. doi:10.1002/hlca.19590420638.
- Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. (1958). "Konstitutionsaufklärung und Synthese von Psilocybin" [The composition and synthesis of psilocybin]. Cellular and Molecular Life Sciences (in German) 14 (11): 397–9. doi:10.1007/BF02160424.
- Nichols DE, Frescas S. (1999). "Improvements to the synthesis of psilocybin and a facile method for preparing the o-acetyl prodrug of psilocin". Synthesis 6 (6): 935–8. doi:10.1055/s-1999-3490.
- O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JR, D'Arecca MA. (eds.) (2001). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (13th ed.). Whitehouse Station, New Jersey: Merck. p. 1419. ISBN 978-0-911910-13-1.
- Jenkins AJ. (2003). "Hallucinogens". In Levine B. Principles of Forensic Toxicology (2nd ed.). Washington, DC: American Association for Clinical Chemistry Press. p. 281. ISBN 978-1-890883-87-4.
- Cole MD. (2003). The Analysis of Controlled Substances. New York, Chichester: John Wiley and Sons. pp. 132–3. ISBN 978-0-471-49252-8.
- Bresinsky A, Besl H. (1989). A Colour Atlas of Poisonous Fungi: A Handbook for Pharmacists, Doctors, and Biologists. London, UK: Manson Publishing. p. 113. ISBN 0-7234-1576-5.
- Kamata T, Katagi M, Tsuchihashi H. (2010). "Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan". Forensic Toxicology 28 (1): 1–8. doi:10.1007/s11419-009-0087-9.
- Pedersen-Bjergaard S, Sannes E, Rasmussen K, Tonneson F. (1997). "Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis". Journal of Chromatography 694 (2): 375–81. doi:10.1016/S0378-4347(97)00127-8. PMID 9252052.
- Lee RE. (1985). "A technique for the rapid isolation and identification of psilocin from psilocin/psilocybin-containing mushrooms". Journal of Forensic Science 30 (3): 931–41. doi:10.1520/JFS11028J.
- Wurst M, Kysilka R, Koza T. (1992). "Analysis and isolation of indole alkaloids of fungi by high-performance liquid chromatography". Journal of Chromatography 593 (1–2): 201–8. doi:10.1016/0021-9673(92)80287-5.
- Saito K, Toyo'oka T, Fukushima T, Kato M, Shirota O, Goda Y. (2004). "Determination of psilocin in magic mushrooms and rat plasma by liquid chromatography with fluorimetry and electrospray ionization mass spectrometry". Analytica Chimica Acta 527 (2): 149–56. doi:10.1016/j.aca.2004.08.071.
- Lindenblatt H, Kramer E, Holzmann-Erens, Gouzoulis-Mayfrank E, Kovar K. (1998). "Quantitation of psilocin in human plasma by high performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction". Journal of Chromatography 709 (2): 255–63. doi:10.1016/S0378-4347(98)00067-X. PMID 9657222.
- Rodriguez-Cruz SE. (2005). "Analysis and characterization of psilocybin and psilocin using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) with collision-induced-dissociation (CID) and source-induced dissociation (SID)". Microgram Journal 3 (3–4): 175–82.
- Sticht G, Käferstein H. (2000). "Detection of psilocin in body fluids". Forensic Science International 113 (1): 403–7. doi:10.1016/S0379-0738(00)00213-9. PMID 10978655.
- Kysilka R. (1990). "Determination of psilocin in rat urine by high-performance liquid chromatography with electrochemical detection". Journal of Chromatography 534: 287–90. doi:10.1016/S0378-4347(00)82176-3. PMID 2094720.
- Grieshaber AF, Moore KA, Levine B. (2001). "The detection of psilocin in human urine". Journal of Forensic Sciences 46 (3): 627–30. PMID 11373000.
- Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. (2003). "Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples". Journal of Chromatography B 792 (2): 421–7. doi:10.1016/j.jchromb.2003.08.030.
- Albers C, Köhler H, Lehr M, Brinkmann B, Beike J. (2004). "Development of a psilocin immunoassay for serum and blood samples". International Journal of Legal Medicine 118 (6): 326–31. doi:10.1007/s00414-004-0469-9. PMID 15526212.
- Lurie I, Li L. (2009). "Use of high-temperature liquid chromatography with sub-2 µm particle C18 columns for the analysis of seized drugs". Journal of Liquid Chromatography & Related Technologies 32 (17–20): 2615–26. doi:10.1080/10826070903245516.
- Attema-de Jonge ME, Portier CB, Franssen EJF. (2007). "Automutilatie na gebruik van hallucinogene paddenstoelen" [Automutilation after consumption of hallucinogenic mushrooms]. Nederlands Tijdschrift voor Geneeskunde (in Dutch) 151 (52): 2869–72. PMID 18257429.
- Adams JD Jr. (2009). "Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex: control of pain and anxiety". Current Medicinal Chemistry 16 (27): 3476–9. doi:10.2174/092986709789057626. PMID 19799545.
- Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. (1998). "Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action". NeuroReport 9 (17): 3897–902. doi:10.1097/00001756-199812010-00024. PMID 9875725.
- Halberstadt AL, Geyer MA. (2011). "Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens". Neuropharmacology 61 (3): 364–81. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631. PMID 21256140.
- Karch SB. (2007). Pharmacokinetics and Pharmacodynamics of Abused Drugs. Boca Raton, Florida: CRC Press. p. 148. ISBN 978-1-4200-5458-3.
- Coull JT, Cheng R-K, Meck WH. (2011). "Neuroanatomical and neurochemical substrates of timing". Neuropsychopharmacology Reviews 36 (1): 3–25. doi:10.1038/npp.2010.113. PMC 3055517. PMID 20668434.
- Bray JK, Goddard III WA. (2008). "The structure of human serotonin 2c G-protein coupled receptor bound to agonists and antagonists". Journal of Molecular Graphics and Modelling 27 (1): 66–81. doi:10.1016/j.jmgm.2008.02.006. PMID 18499489.
- González-Maeso J, Sealfon SC. (2009). "Agonist-trafficking and hallucinogens". Current Medicinal Chemistry 16 (8): 1017–27. doi:10.2174/092986709787581851. PMID 19275609.
- Gable RS. (2006). "Acute toxicity of drugs versus regulatory status". In Fish JM. Drugs and Society: U.S. Public Policy. Lanham, Maryland: Rowman & Littlefield. pp. 149–62; Table 7.1 "Safety Ratio and Dependence Potential of Psychoactive Drugs". ISBN 0-7425-4245-9.
- Gable RS. (2004). "Comparison of acute lethal toxicity of commonly abused psychoactive substances" (PDF). Addiction 99 (6): 686–96. doi:10.1111/j.1360-0443.2004.00744.x. PMID 15139867.
- Strassman R, Wojtowicz S, Luna LE, Frecska E. (2008). Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies. Rochester, Vermont: Park Street Press. p. 147. ISBN 978-1-59477-224-5.
- Gérault A, Picart D. (1996). "Intoxication mortelle à la suite de la consommation volontaire et en groupe de champignons hallucinogènes" [Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms]. Bulletin de la Société Mycologique de France (in French) 112: 1–14.
- Gartz J, Samorini G, Festi F. (1996). "On the presumed French case of fatality caused by ingestion of Liberty Caps". Eluesis 6: 40–1.
- Chen C-Y, Storr CL, Anthony JC. (2008). "Early-onset drug use and risk for drug dependence problems". Addictive Behaviors 34 (3): 319–22. doi:10.1016/j.addbeh.2008.10.021. PMC 2677076. PMID 19022584.
- van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. (2010). "Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population". European Addiction Research 16 (4): 202–7. doi:10.1159/000317249. PMID 20606445.
- Nutt DJ, King LA, Phillips LD. (2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet 376 (9752): 1558–65. doi:10.1016/S0140-6736(10)61462-6. PMID 21036393.
- Pagliaro LA, Pagliaro AM. (2012). Handbook of Child and Adolescent Drug and Substance Abuse: Pharmacological, Developmental, and Clinical Considerations (2nd ed.). Hoboken, New Jersey: John Wiley & Sons. p. 199. ISBN 978-0-470-63906-1.
- Schaefer C. (2001). Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. Amsterdam, The Netherlands: Elsevier. p. 222. ISBN 978-0-444-50763-1.
- Stamets (1996), pp. 36–41.
- Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. (2002). "Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man". Journal of Pharmaceutical and Biomedical Analysis 30 (2): 331–9. doi:10.1016/S0731-7085(02)00278-9. PMID 12191719.
- Meyer MR, Maurer HH. (2011). "Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse". Pharmacogenomics 12 (2): 215–33. doi:10.2217/pgs.10.171. PMID 21332315.
- Baselt RC. (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, California: Biomedical Publications. pp. 1346–8. ISBN 0-9626523-7-7.
- Ballesteros et al. (2006), p. 171.
- Nicholas LG, Ogame K. (2006). Psilocybin Mushroom Handbook: Easy Indoor and Outdoor Cultivation. Oakland, California: Quick American Archives. p. 164. ISBN 978-0-932551-71-9.
- Passie T, Halpern JH, Stichtenoth, Emrich HM, Hintzen A. (2008). "The pharmacology of lysergic acid diethyamide: a review". CNS Neuroscience & Therapeutics 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.
- Beck O, Helander A, Karlson-Stiber C, Stephansson N. (1998). "Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions". Journal of Analytical Toxicology 22 (1): 45–9. doi:10.1093/jat/22.1.45. PMID 9491968.
- van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A. (2006). "Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction". Life Sciences 79 (21): 1969–73. doi:10.1016/j.lfs.2006.06.010. PMID 16884739.
- Berge JT. (1999). "Breakdown or breakthrough? A history of European research into drugs and creativity". Journal of Creative Behavior 33 (4): 257–76. doi:10.1002/j.2162-6057.1999.tb01406.x. ISSN 0022-0175.
- Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. (2004). "Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study". Psychopharmacology 172 (2): 145–56. doi:10.1007/s00213-003-1640-6. PMID 14615876.
- Ballesteros et al. (2006), p. 175.
- MacLean KA, Johnson MW, Griffiths RR. (2011). "Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness". Journal of Psychopharmacology 25 (11): 1453–61. doi:10.1177/0269881111420188. PMC 3537171. PMID 21956378.
- Frecska E, Luna LE. (2006). "The adverse effects of hallucinogens from intramural perspective" (PDF). Neuropsychopharmacolia Hungarica 8 (4): 189–200. PMID 17211054.
- Quentin A-M. (1960). La Psilocybine en Psychiatrie Clinique et Experimentale [Psilocybin in Clinical and Experimental Psychiatry] (PhD thesis) (in French). Paris, France: Paris University Medical Dissertation.
- See for example:
- Isbell H. (1959). "Comparison of the reactions induced by psilocybin and LSD-25 in man". Psychopharmacologia 1 (1): 29–38. doi:10.1007/BF00408109. PMID 14405870.
- Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N. (1960). "Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects". Journal of Nervous and Mental Disease 131 (5): 428–34. doi:10.1097/00005053-196011000-00007. PMID 13715375.
- Malitz S, Esecover H, Wilkens B, Hoch PH. (1960). "Some observations on psilocybin, a new hallucinogen, in volunteer subjects". Comprehensive Psychiatry 1: 8–17. doi:10.1016/S0010-440X(60)80045-4. PMID 14420328.
- Rinkel M, Atwell CR, Dimascio A, Brown J. (1960). "Experimental psychiatry. V. Psilocybine, a new psychotogenic drug". New England Journal of Medicine 11 (262): 295–7. doi:10.1056/NEJM196002112620606. PMID 14437505.
- Parashos AJ. (1976). "The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics". Behavioral Neuropsychiatry 8 (1–12): 83–6. PMID 1052267.
- Heimann H. (1994). "Experience of time and space in model psychoses". In Pletscher A, Ladewig D (eds.). 50 Years of LSD. Current Status and Perspectives of Hallucinogens. New York, New York: The Parthenon Publishing Group. pp. 59–66. ISBN 1-85070-569-0.
- Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. (2007). "Effects of psilocybin on time perception and temporal control of behaviour in humans". Journal of Psychopharmacology (Oxford) 21 (1): 50–64. doi:10.1177/0269881106065859. PMID 16714323.
- Wackermann J, Wittmann M, Hasler F, Vollenweider FX. (2008). "Effects of varied doses of psilocybin on time interval reproduction in human subjects". Neuroscience Letters 435 (1): 51–5. doi:10.1016/j.neulet.2008.02.006. PMID 18325673.
- Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. (2005). "Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors". Journal of Cognitive Neuroscience 17 (10): 1497–508. doi:10.1162/089892905774597191. PMID 16269092.
- Harrington DL, Haaland KY. (1999). "Neural underpinnings of temporal processing: a review of focal lesion, pharmacological, and functional imaging research". Reviews in the Neurosciences 10 (2): 91–116. doi:10.1515/REVNEURO.19126.96.36.199. PMID 10658954.
- Stafford (1992), p. 273.
- Peden NR, Pringle SD, Crooks J. (1982). "The problem of psilocybin mushroom abuse". Human Toxicology 1 (4): 417–24. doi:10.1177/096032718200100408. PMID 7173927.
- Hyde C, Glancy P, Omerod P, Hall D, Taylor GS. (1978). "Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications". British Journal of Psychiatry 132 (6): 602–4. doi:10.1192/bjp.132.6.602. PMID 566144.
- Mack RB. (1983). "Phenomenally phunny phungi – psilocybin toxicity". New Castle Medical Journal 44 (10): 639–40. PMID 6580536.
- Carhart-Harris RL, Nutt DJ. (2010). "User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study". Journal of Substance Abuse 15 (4): 283–300. doi:10.3109/14659890903271624.
- Simeon D. (2004). "Depersonalisation disorder: a contemporary overview". CNS Drugs 18 (6): 343–54. doi:10.2165/00023210-200418060-00002. PMID 15089102.
- Geyer MA. (1998). "Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research". Pharmacopsychiatry 31 (S2): 73–9. doi:10.1055/s-2007-979350. PMID 9754837.
- Vollenweider FX, Geyer MA. (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. PMID 11750795.
- Geyer MA, Vollenweider FX. (2008). "Serotonin research: contributions to understanding psychoses". Trends in Pharmacological Sciences 29 (9): 445–53. doi:10.1016/j.tips.2008.06.006. PMID 19086254.
- Myers LS, Watkins SS, Carter TJ. (1998). "Flashbacks in theory and practice" (PDF). The Heffter Review of Psychedelic Research 1: 51–7.
- Winkelman MJ. (2007). "Therapeutic bases of psychedelic medicines: psychointegrative effects". In Winkelman MJ, Roberts TB. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments 1. Westport, Connecticut: Praeger. pp. 1–19. ISBN 978-0-275-99024-4.
- McKenna T. (1993). Food of the Gods: The Search for the Original Tree of Knowledge. A Radical History of Plants, Drugs, and Human Evolution. New York, New York: Bantam Books. ISBN 978-0-553-37130-7.
- James W. (1902). The Varieties of Religious Experience. New York, New York: Simon & Schuster. ISBN 978-0-684-84297-4.
- Metzner R. (1998). "Hallucinogenic drugs and plants in psychotherapy and shamanism". Journal of Psychoactive Drugs 40 (4): 333–41. doi:10.1080/02791072.1998.10399709. PMID 9924839.
- Pahnke WN, Richards W. (1966). "Implications of LSD and experimental mysticism". Journal of Religion and Health 5 (3): 175–208. doi:10.1007/BF01532646.
- Pahnke WN. (1966). "Drugs and mysticism". International Journal of Parapsychology 8 (2): 295–315.
- Griffiths R, Richards W, Johnson M, McCann U, Jesse R. (2008). "Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later" (PDF). Journal of Psychopharmacology 22 (6): 621–32. doi:10.1177/0269881108094300. PMC 3050654. PMID 18593735.
- Smith H. (2000). Cleansing the Doors of Perception: The Religious Significance of Entheogenic Plants and Chemicals. New York, New York: Jeremy P. Tarcher/Putnam. p. 101. ISBN 978-1-58542-034-6.
- Doblin (1991), p. 13.
- Doblin (1991), p. 24.
- Richards WA. (2008). "The phenomenology and potential religious import of states of consciousness facilitated by psilocybin". Archive for the Psychology of Religion 30 (1): 189–99. doi:10.1163/157361208X317196.
- Griffiths RR, Richards WA, McCann U, Jesse R. (2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance" (PDF). Psychopharmacology 187 (3): 268–83. doi:10.1007/s00213-006-0457-5. PMID 16826400.
- "Press release: Griffiths psilocybin". Johns Hopkins Medicine. July 11, 2006.
- Hood RW Jr. (1975). "The construction and preliminary validation of a measure of reported mystical experience". Journal for the Scientific Study of Religion 14 (1): 29–41. doi:10.2307/1384454. JSTOR 1384454.
- Smith M. (Jul 12, 2006). "Medical News: Psilocybin Viewed as Therapy or Research Tool". Medpagetoday.com. Retrieved 2011-02-12.
- Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. (2011). "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects". Psychopharmacology 218 (4): 649–65. doi:10.1007/s00213-011-2358-5. PMC 3308357. PMID 21674151. Lay summary – Newswise.com (2011-06-13).
- Wark C, Galliher JF. (2009). "Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin". The International Journal on Drug Policy 21 (3): 234–9. doi:10.1016/j.drugpo.2009.08.004. PMID 19744846.
- Brown D. (11 July 2006). "Drug's mystical properties confirmed". Washington Post. Retrieved 2011-09-12.
- Marley (2010), pp. 179–81.
- Associated Press (20 December 2006). "Psychedelic mushrooms ease OCD symptoms". msnbc.com. Retrieved 2011-11-23.
- Kellner M. (2010). "Drug treatment of obsessive-compulsive disorder". Dialogues in Clinical Neuroscience 12 (2): 187–97. PMC 3181958. PMID 20623923.
- Vollenweider FX, Kometer M. (2010). "The neurobiology of psychedelic drugs: implications for the treatment of mood disorders". Nature Reviews Neuroscience 11 (9): 642–51. doi:10.1038/nrn2884. PMID 20717121.
- Sun-Edelstein C, Mauskop A. (2011). "Alternative headache treatments: nutraceuticals, behavioral and physical treatments". Headache: the Journal of Head and Face Pain 51 (3): 469–83. doi:10.1111/j.1526-4610.2011.01846.x. PMID 21352222.
- Husid MS. (2007). "Cluster headache: a case-based review of diagnostic and treatment approaches". Current Pain and Headache Reports 10 (2): 117–25. doi:10.1007/s11916-006-0022-2. PMID 16539864.
- Bone E. (2011). Mycophilia: Revelations from the Weird World of Mushrooms. New York, New York: Rodale. pp. 257–8. ISBN 978-1-60529-407-0.
- European Monitoring Centre for Drugs and Drug Addiction (November 2011) (PDF). Annual report 2011: the state of the drugs problem in Europe (Report). Luxembourg: Publications Office of the European Union. doi:10.2810/44330. ISBN 978-92-9168-470-0. http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf.
- Guzmán G. (2008). "Hallucinogenic mushrooms in Mexico: an overview". Economic Botany 62 (3): 404–12. doi:10.1007/s12231-008-9033-8.
- Boire (2002), p. 25.
- Boire (2002), p. 26.
- "List of psychotropic substances under international control" (PDF) (23rd ed.). Vienna, Austria: International Narcotics Control Board. August 2003.
- Ballesteros et al. (2006), pp. 178–9.
- Ballesteros S, Ramon MF, Iturralde MJ, Martinez-Arrieta R. (2006). "Natural sources of drugs of abuse: magic mushrooms". In Cole SM. New Research on Street Drugs. New York, New York: Nova Publishers. pp. 167–88. ISBN 978-1-59454-961-8.
- Boire (2002), pp. 25–48.
- Marley (2010), pp. 177–8.
- Ballesteros S, Ramón MF, Iturralde MJ, Martínez-Arrieta R. (2006). "Natural sources of drugs of abuse: magic mushrooms". In Cole SM. New Research on Street Drugs. New York, New York: Nova Science Publishers. pp. 167–86. ISBN 978-1-59454-961-8.
- Boire RG. (2002). Sacred Mushrooms and the Law. Berkeley, California: Ronin Publishing. ISBN 978-1-57951-061-9.
- Doblin R. (1991). "Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique" (PDF). Journal of Transpersonal Psychology 23 (1): 1–25.
- Gartz J. (1997). Magic Mushrooms Around the World. Los Angeles, California: LIS Publications. ISBN 978-0-9653399-0-2.
- Marley G. (2010). "Psilocybin: gateway to the soul or just a good high?". Chanterelle Dreams, Amanita Nightmares: The Love, Lore, and Mystique of Mushrooms. White River Junction, Vermont: Chelsea Green Publishing. pp. 163–84. ISBN 1-60358-214-2.
- Ott J. (1993). Pharmacotheon: Entheogenic Drugs, their Plant Sources and History. Kennewick, Washington: Natural Products Company. ISBN 978-0-9614234-3-8.
- Stafford PJ. (1992). Psychedelics Encyclopedia (3rd ed.). Berkeley, California: Ronin Publishing. ISBN 0-914171-51-8.
- Stamets P. (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. ISBN 0-89815-839-7.
- Wurst M, Kysilka R, Flieger M. (2002). "Psychoactive tryptamines from Basidiomycetes". Folia Microbiologica 47 (1): 3–27. doi:10.1007/BF02818560. PMID 11980266.
- Hopkins/CSP research findings and media reports, 2006, 2008, 2011
- MAPS Psilocybin research